CD4 and myeloid sarcoma: As shown (Figure 4), patients affected by EMS with MS show an increase in Treg subset (Figure 4A) (Foxp3 CD4 EMS vs. Foxp3 CD4 EMS-MS, p = 0.32); a higher expression trend was also observed in the exon 2 Foxp3 transcription factor (Figure 4B) (Foxp3 CD4 ex2 EMS vs. Foxp3 CD4 ex2 EMS-MS, p = 0.27), largely associated with effective immune-modulating properties of the Treg population.